ANI Pharmaceuticals (ANIP) Scheduled to Post Quarterly Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) will issue its quarterly earnings data before the market opens on Friday, May 10th. Analysts expect the company to announce earnings of $0.98 per share for the quarter. ANI Pharmaceuticals has set its FY24 guidance at $4.26-4.67 EPS and its FY 2024 guidance at 4.260-4.670 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The firm had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:ANIP opened at $66.72 on Wednesday. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of 79.43 and a beta of 0.80. The company has a 50 day moving average of $66.86 and a two-hundred day moving average of $59.32. ANI Pharmaceuticals has a 52-week low of $38.91 and a 52-week high of $70.81. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 7,414 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the transaction, the chief operating officer now directly owns 825,206 shares in the company, valued at $54,735,913.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Muthusamy Shanmugam sold 7,414 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $66.33, for a total transaction of $491,770.62. Following the completion of the sale, the chief operating officer now owns 825,206 shares of the company’s stock, valued at approximately $54,735,913.98. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Nikhil Lalwani sold 28,965 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at approximately $29,155,155.12. The disclosure for this sale can be found here. Insiders have sold 176,803 shares of company stock worth $11,695,866 over the last quarter. 12.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ANIP. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Guggenheim reissued a “buy” rating and issued a $77.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Capital One Financial began coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective on the stock. Finally, HC Wainwright increased their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $80.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.